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 Abstract 
Objectives: Inflammation related enteric dysmotility has been postulated as a 
cause for abdominal symptoms in Crohn’s disease (CD). We investigated the 
relationship between MRI-quantified small bowel (SB) motility, inflammatory 
activity and patient symptom burden. 
 
Methods: The Harvey Bradshaw Index (HBI) and fecal calprotectin were 
prospectively measured in 53 CD patients (median age 35, range 18-78) the day 
before MRI enterography which included a dynamic (cine), breath-hold motility 
sequence, repeated to encompass the whole SB volume.  A validated registration 
based motility quantitation technique produced motility maps and regions of 
interest were drawn to include all morphologically normal SB (i.e. excluding 
diseased bowel). Global SB motility was correlated with calprotectin, HBI and 
symptom components (wellbeing, pain, diarrhea). Adjustment for age, sex, 
smoking and surgical history was made using multivariate linear regression.  
 
Results: Median calprotectin was 336 (range 0-1280).  Mean HBI, motility mean 
and motility variance were 3 (range 0-16), 0.33 (0.18 to 0.51) and 0.01 (0.0014 to 
0.034) respectively. Motility variance was significantly negatively correlated with 
calprotectin (Rho = -0.33, P = 0.015), total HBI (rho = -0.45, P <0.001), wellbeing 
(rho= -0.4, p=0.003), pain (rho = -0.27, p =0.05) and diarrhea (rho= -0.4, 
p=0.0025). The associations remained highly significant after adjusting for 
covariates. There was no association between mean motility and calprotectin or 
HBI (p>0.05). 
 
Conclusions: Reduced motility variance in morphologically normal small bowel is 
associated with patient symptoms and fecal calprotectin levels, supporting the 
hypothesis that inflammation related enteric dysmotility may explain refractory 
abdominal symptoms in CD.  
  
 
 
WHAT IS CURRENT KNOWLEDGE  
 Abdominal symptoms often persist in Crohn’s disease patients despite 
successful immunosuppressive therapy and full mucosal healing. 
 Irritable bowel syndrome symptoms are more common in Crohn’s patients 
with raised calprotectin levels when in clinical remission.  
 Aberrant small bowel motility remote from diseased segments has been 
postulated as a cause for refractory symptoms, although supportive data 
are limited. 
 
WHAT IS NEW HERE  
 Reduction in the normal variability of small bowel motility quantified using 
cine MRI is associated with increased abdominal symptoms in CD patients 
and with disease related inflammatory burden based on  faecal calprotectin 
 Inflammation related enteric dysmotility may explain some abdominal 
symptoms in Crohn’s disease (CD).   
 Introduction 
 
Crohn’s disease (CD) manifests as lifelong, relapsing and remitting inflammation 
of the gut and is conventionally treated using immunosuppressives to reduce 
inflammation and subsequent bowel damage including stricturing and 
fistulation1. It is well recognized that there is a discord between apparent 
therapeutic success (such as endoscopic mucosal healing) and resolution of 
patient symptoms including pain, and general wellbeing 2,3. Indeed, 20% of 
patients achieving near endoscopic normality after treatment have little or no 
improvement in symptom burden4,5.  
 
Gut inflammation, whether mediated by abnormal immune response or via 
infection, has been consistently demonstrated to alter gut function in pre-clinical 
models and likely occurs via a combination of structural, neuronal, immunological 
and hormonal changes 6–10. These changes lead to abnormal secretion, sensation 
and motility of the gut which could precipitate functional symptoms including 
abdominal pain and diarrhea 11–13. Oro-cecal transit time for example has been 
shown to be reduced in active CD14 whilst gastric emptying is apparently 
attenuated 15,16. Furthermore, irritable bowel syndrome type symptoms are more 
common in Crohn’s patients with raised calprotectin even when clinically 
otherwise in remission17. 
 
To date, limited data regarding aberrant motility in IBD has been derived by 
assessing transit (using radiographic markers or radiolabelled foodstuffs) or via 
invasive manometric measurement18,19. Whilst validated for functional 
conditions, their utility in IBD has not been established. More recently, MRI with 
quantitative analysis has been used to non-invasively explore segmental and 
whole gut motility20–24. In a small pilot study of 13 CD patients, Bickelhaupt et al 
found a negative relationship between intestinal motility and inflammatory 
markers (CRP and faecal calprotectin (fC)) in apparently normal bowel21. Such 
data suggests that simple cine MRI motility sequences, easily added to standard 
MR enterography protocols, could provide greater insight into deregulated 
motility in CD and its role in the etiology of patient symptoms.  
 
The aim of this prospective study was to investigate the relationship between MRI 
quantified intestinal motility in morphologically normal bowel against i) 
inflammatory and ii) subjective symptom burden measured by faecal calprotectin 
and Harvey Bradshaw index respectively in patients with CD.  
  
Methods 
Patient selection 
 
Consecutive patients with known or suspected Crohn’s disease and referred for 
MR enterography were recruited prospectively at a single center between 
February 2010 and October 2011. 
 
 In patients with suspected CD, only those patients with a final positive diagnosis 
based on clinical, biochemical, endoscopic, imaging and histopathological findings 
were ultimately included in the current study. Research ethics committee 
approval (Hampstead REC, North London) was obtained and all patients gave 
informed written consent.  
 
Patients completed a Harvey Bradshaw Index (HBI) symptom questionnaire the 
day before the MRI25  and provided a stool sample on the morning of the MRI to 
facilitate same-day measurement of fecal calprotectin (fC) (PhilCal; NovaTec 
Immunodiagnostica, Dietzenbach, Germany). Individual responses to HBI 
parameters of diarrhea, pain and wellbeing were recorded. Demographic data 
including age, sex, disease duration, Crohn’s disease related medication, smoking 
status, body mass index and surgical history were also documented. The patient 
cohort has in part been previously been described by Makanyanga et al26 but here 
we report analysis of motility data, which has not previously been described. For 
the purposes of the current study, patients were excluded if they had a stoma, 
failed to undergo dynamic MRI cine sequences (see below) or were taking 
medication with known motility altering affects including pro-kinetic and 
antiemetic agents, spasmolytic (including Buscopan) and opioid analgesics.  
 
MRI Protocol 
 
Magnetic Resonance Enterography (MRE) was performed using standardized 
clinical protocols on either a 1.5T (Avanto, Siemens, Medical Systems, Erlangen, 
Germany) or 3T (Achieva; Philips, Best, The Netherlands) unit. Patients fasted for 
4 hours before ingesting 1 to 1.5L of 0.2% locust bean gum/2.5% mannitol 
solution over 45 min. The MRE protocol commenced with dynamic, motility ‘cine’ 
imaging (Appendix 1) before hyoscine butylbromide was administered and 
anatomical sequences were performed.  
 
Trained MRI radiographers acquired single-plane time series images with a 1cm 
slice thickness to capture bowel motility. The temporal resolution at both field 
strengths was 1 image per second acquired over a 20s breath-hold. Each single 
slice breath hold motility acquisition was repeated multiple times moving the slice 
position sequentially from the posterior to the anterior abdomen, to encompass 
as much of the total small bowel volume as possible. Between 7 and 15 positions 
were required depending on body habitus.  
 
Motility assessment 
 
Imaging datasets were anonymized and downloaded into a graphical user 
interface for motility analysis written in MATLAB (The MathWorks, Natick, MA, 
USA). All motility analysis was performed using validated software based on optic 
flow registration, including contrast changes27. A full description of the software 
has been previously published27. In brief, the registration algorithm corrects local 
deformation generated by bowel wall motion. The resulting set of deformation 
fields are analyzed by taking the standard deviation of each pixels Jacobian 
determinant through time to produce a parametric motility map, serving as a 
surrogate of bowel wall motion (figure 1A-D). Regions of interest (ROIs) can be 
manually applied to a particular segment or, alternatively, the entire bowel 
volume. This technique has been validated and shown to be repeatable and 
sensitive to drug-induced changes in motility 24. It has previously been 
successfully applied in segmental CD 22 and Chronic Intestinal Pseudo-
Obstruction28.   
 
Three motility metrics were implemented based on ROIs drawn by a 
gastroenterologist (4 years experience with MRE) in consensus with a GI 
radiologist with 9 years of experience in small bowel MRI, both blinded to all 
clinical information. For all metrics, only small bowel with a normal appearance 
across all acquired MRI sequences was sampled i.e. any small bowel with typical 
MRI stigmata of Crohn’s disease such as mural thickening (>3mm), abnormal 
mural T2 signal and increased contrast enhancement was excluded in any ROI 
placement 29. 
 
 Metric 1: Contractions per minute 
The contractions per minute is a semi-objective motility metric based on the 
change in luminal diameter of the bowel when observed in the coronal plane 21.  
In detail, two linear regions of interest (ROIs) were placed, each in a different 
quadrant containing well-distended morphologically normal bowel remaining in 
plane throughout the cine time series.  Regions were drawn on one frame of the 
selected time series across the lumen of the chosen loop (from outer bowel wall 
to outer bowel wall Figure 2A) and then automatically propagated through the series 
by the analysis software27.  
 
The number of contractions (defined as a reduction in luminal diameter of more than 
10% of the overall mean for the 20 second breath hold time period) was recorded at 
each ROI  and multiplied by 3 to give a number of contractions per minute (CPM) 
(figure 2B,C)30,31. The mean of the two CPM scores (i.e. one from each ROI) was 
taken as the measure of contractile activity. 
 
Metric 2: mean global motility 
The observers drew a ROI on one frame of each acquired cine time series to 
encompass the whole small bowel volume for each patient. Again, only 
morphologically normal bowel was included in the ROI and abnormal bowel, 
colon, static structures such as solid organs and mesenteric fat were excluded. If 
necessary, several large ROIs were drawn on the coronal image to encompass all 
visible normal small bowel (Figure 1). Previous reference ranges from a cohort of 
healthy volunteers suggested the mean small bowel contraction rate was 5cpm 
(range 0 to 15). 
 
A mean global small bowel motility score was calculated by averaging the SD 
Jacobian parametric map values under each ROI across all the breath hold time 
series. Examples of low and high small bowel motility can be seen in figure 1A and 
2B respectively. Previous reference ranges from a cohort of healthy volunteers 
suggested mean global motility (mean) score of 0.34 (Range 0.28 to 0.395) 
 
Metric 3: Variance of global Motility 
The same ROIs were utilized as per metric 2. However the variance of the SD 
Jacobian parametric map values under each ROI across the small bowel volume 
was calculated. A high motility variance score implies a large range of motility 
values across the small bowel volume i.e. bowel motion is heterogeneous.  An 
illustrative example of the spread of mean motility and variance from the patient 
cohort is show in figure 1. Previous reference ranges from a cohort of healthy 
volunteers suggested mean global motility variance score of 0.03 (range 0.02 to 
0.04) 
 
Statistical analysis 
 
All data were assessed for normality using the Shapiro-Wilk test (alpha = 0.05); 
non-parametric statistics were used where data were non-normally distributed.  
 
Correlation assessment between the 3 motility metrics, fC and HBI was performed 
using Spearman’s Rho and then multivariate linear regression after accounting for 
the following covariates: Age, sex, current smoking status (smoker/non-smoker), 
Crohn’s disease specific medication (Table 1), previous history of surgery 
(yes/no), body mass index, and number of years since diagnosis. Correlation was 
also calculated between each of the HBI symptom parameters (wellbeing, pain and 
liquid stools) and each motility metric, subsequently repeated using ordinal 
logistic regression (for pain and wellbeing) and negative binomial regression (for 
number of diarrheal stools/day) to account for the same covariates as above. In 
addition, the fecal calprotectin level was included as a measure of total 
inflammatory burden. To determine the strength of association of each motility 
metric, a simpler regression model without that metric as a predictor was 
compared to the full model using the likelihood ratio test, with p<0.05 taken as 
being significant for all analyses. In addition a simple correlation was performed 
between a global MR disease activity score (Magnetic Resonance Enterography 
Global Score (MEGS)  described in Makanyange et al. 26) and the three motility 
metrics.  
 
All statistical analysis was performed using MATLAB (The Mathworks, Natick, 
MA) or R for Mac version 3.0.1 (R Core Team, Vienna, Austria). 
  
 Results 
Cohort Demographics 
 
71 patients were recruited and underwent MRI enterography. Eighteen patients 
were excluded (10 female). 8 were taking motility influencing medication known 
to affect bowel motility, 6 had a stoma and 4 had missing dynamic sequences 
leaving a total of 53 subjects in the final study cohort (median age 35, range 18 to 
78). Median disease duration was 6 years (range 0 to 32). 25 of the cohort had 
ileocolonic disease, 17 and 11 had isolated colonic and small bowel disease 
respectively. 14 of the 53 patients had a stricturing disease phenotype. A summary 
of patient demographics is presented in table 1.  
 
Motility metrics, fC and HBI 
 
A summary of motility metrics, calprotectin level and HBI score is provided in 
table 2. 
 
There was no significant correlation between fC and HBI, R = -0.06, P = 0.65 . 
There was there no significant correlation between the MEGS score and motility 
assessed by global variance, global mean and CPM metrics (R = -0.02, p = 0.88, R = 
-0.034, p = 0.8 & R = -0.09, p = 0.52 respectively).  
 
There was a statistically significant negative correlation between global small 
bowel motility variance (metric 3) and both fC and total HBI (r=-0.33, p=0.015 and 
R=-0.45, p<0.001 (figure 3) respectively).  After applying the multivariate 
regression model, global small bowel motility variance retained a significant 
negative association with both fC (p=0.04) and HBI (p=0.0005). The regression 
models showed that for each 0.01 unit increase in global small bowel motility 
variance, there was an associated 2.5 unit drop in HBI and a 145 micrograms/g 
drop in fC. 
 
Neither contraction rate per minute (metric1) nor mean global motility (metric 2) 
showed any significant relationship to fC or HBI (table 3), either by simple 
correlation or by multivariate regression. 
 
Stratified assessment of the Harvey-Bradshaw index indices 
 
 There was significant inverse correlation between global motility variance and 
wellbeing, abdominal pain and the number of liquid stools (table 4). These 
differences retained significance in the regression models following adjustment 
for covariates: Lower global motility variance scores were statistically 
significantly associated with worse HBI wellbeing scores (p=0.00046). Overall, for 
each 0.01 reduction in the global motility variance score, the odds of a patient 
giving a higher (ie worse) HBI wellbeing score increased by 0.19 (95% CI 0.06-
0.50). Similarly, lower global motility variance scores were associated with higher 
pain scores (p=0.0043). For each 0.01 reduction in global motility variance, the 
odds of a higher abdominal pain score increased by 0.26 (95% CI 0.08-0.67). 
Finally, the number of diarrheal stools/day was also significantly associated with 
lower global motility variance (p=0.0001), with each 0.01 reduction in global 
motility variance increasing the rate of an additional diarrheal stool by 0.39/day 
(95%CI 0.23-0.61). Of the other covariates assessed, smoking and BMI were 
significantly association with abdominal pain, and female sex and disease duration 
were significantly associated with the number of diarrheal stools (Table 5).   
 
Contractions per minute and mean global motility were not significantly 
associated with wellbeing (p=0.30 and p=0.32 for CPM and mean global motility 
respectively), abdominal pain (p=0.66 and p=0.32) or number of diarrheal stools 
(p=0.34 and p=0.62). 
 
  
Discussion 
 
This study has demonstrated a significant negative association between a global 
MRI measure of motility variance in apparently normal bowel and both 
inflammatory and symptom burden in CD. 
 
Fecal calprotectin (fC) is a marker of mucosal CD activity, correlates with excretion 
of 111indium-labelled granulocytes in stool, CRP, faecal lactoferrin32–36 and 
predicts active disease at endoscopy 37–39. Despite several limitations it seems a 
reasonable marker of global inflammatory burden as an endpoint40. In 
comparison, HBI is a widely used clinical disease severity score and includes 
patient self-reported components such as diarrheal stools,   wellbeing and 
abdominal pain offering an important insight into the functional aspects of patient 
symptoms. As previously described, we found a poor correlation between these 
objective (calprotectin) and more subjective (HBI) markers of disease activity, 
underlining the apparent disconnect between inflammatory burden and patient 
symptoms26,41.  
 
Global bowel motility variance essentially measures the range of motility across 
the bowel taking into account the “peaks and troughs” between and within 
different segments.  It is well established that there is a wide range of contractile 
activity in healthy individuals42–47. Contractility is split broadly into the post-
prandial actions (peristalsis and segmentation) directed at mixing food and aiding 
absorption and the fasted contractility associated with maintaining bowel health 
and function42. In the post prandial state, contractility is varied, with periods of 
quiescence prolonging transit time to aid absorption42,48,49. Across the total small 
bowel volume it therefore follows that motility is heterogeneous (i.e. variable) in 
the postprandial state. It seems intuitive that the altered osmolality induced by 
mannitol, together with the increase in luminal volume, precipitates a largely 
post-prandial response in the gut. In support, healthy subjects demonstrate large 
variations in segmental motility on MRI following an oral contrast load 31.  
 
 We observed decreased motility variation in patients reporting more severe 
abdominal symptoms, supporting the concept that reduction in the expected 
heterogeneity of motility in the post prandial state may be directly related to 
patient symptoms. Furthermore, each of the HBI symptom components (pain, 
wellbeing and diarrheal stools) were all individually correlated with a reduction 
in bowel motility variance. The association with diarrheal stools is interesting and 
possibly reflects a more sustained contractile action with a decrease in periods of 
quiescence required for efficient liquid absorption. The data appears robust as the 
association between motility and HBI components remained after accounting for 
other factors which may influence patient symptoms such as age, sex, surgical 
history, years since diagnosis and smoking. 46,50.  
 
We also found a negative association between bowel motility variance and 
inflammatory burden quantified using fecal calprotectin. Our data therefore 
support the hypothesis that bowel inflammation inhibits the normal healthy 
variability in small bowel motility and that this, in turn, may contribute to 
functional symptoms such as pain and wellbeing.  Indeed, Keohnae et al reported 
higher levels of calprotectin in patients with irritable bowel syndrome like 
symptoms, compared to those without in a cohort of CD patients clinically in 
remission suggesting low grade inflammation underpins abdominal symptoms17. 
Our data suggest aberrant motility may be a novel and measurable manifestation 
of this process. 
 
Existing data on bowel motility in CD are sparse. MRI motility techniques have 
clearly shown reduced motility in affected segments which is directly related to 
the burden of mural inflammation 20,22. However, data on motility in the 
unaffected bowel are limited. Investigations using conventional techniques such 
as transit times and manometry are heterogeneous with decreased transit time14, 
prolonged gastric emptying15,16 and altered anorectal physiology all described 
51,52. A recent small study using MRI in 13 CD patients showed a strong, negative 
correlation between contraction frequency per minute in normal bowel segments 
and fC (R = 0.805, p = 0.001) 21. In addition, a number of pre-clinical investigations 
relate even low-grade inflammatory activity to gut neuroplasticity (structural, 
synaptic or intrinsic changes that alter neuronal function) 53,54.  
   
Although global small bowel motility variance was associated with both fC and 
HBI, our other measured motility metrics showed no relationship to these indices. 
In our larger cohort of patients we were unable to reproduce the data from 
Bickelhaupt et al21. It should be noted however that Bickelhaupt et al. acquired 
data over 60-90 seconds rather than our 20s breath-hold protocol. Although 
motility measured using CPM is perhaps the most widely reported metric it is 
subject to several limitations. Notably, placement of ROIs in morphologically 
normal bowel is subjective, and recent work has shown large intra-segmental 
contraction rate variability in healthy volunteers suggesting high dependence on 
ROI positioning31. Quantification of global (as opposed to segmental) motility 
using software analysis in the current study has been shown to be repeatable over 
time in healthy volunteers. In the current study, no relationship between mean 
global motility was found with either calprotectin or HBI24. This suggests average 
bowel motility itself may not be a strong marker of intestinal dysfunction, perhaps 
in part due to “averaging out” of more subtle changes, better detected by changes 
in motility variability. 
 
There are several limitations in this study. Although two of our motility metrics 
(CPM and mean motility) are well described, the additional measure of motility 
variance is new. However use of this metric was based on the well described 
heterogeneity of small bowel motility in the existing literature. The three motility 
metrics against two outcomes may provide a source Type I statistical error, 
although we think this is unlikely. A second limitation is the use of a breath-hold 
protocol driving the observation of bowel motility where longer time periods 
might provide more robust data. However, the breath-hold technique is well 
validated and more practical for patients without the added analytical complexity 
introduced by free breathing. We standardized the preparation of our patient 
cohort prior to MRI, ensuring all patients were fasted and were provided with the 
same volume of oral contrast agent to be ingested over a standard time period. We 
also excluded patients on medication overtly affected bowel motility. However we 
were unable to control for other factors that could influence motility such as 
gender, time of day, caffeine use and smoking.  Such influences would however 
likely not produce any systematic bias as would be applicable to the whole cohort. 
Furthermore we are able to account for the influence of several such as smoking, 
age and gender in our analysis. We blinded observers to all clinical information, 
although to ensure exclusion of all abnormal bowel they were unblinded to 
anatomical MRI sequences when placing ROIs. It would have been interesting to 
correlate motility in the healthy bowel against endoscopic disease severity in 
affected segments. However, endoscopic data was not universally available in this 
patient cohort.  
 
Although we have shown a relationship between reduced motility variation and 
both patient symptoms and fecal calprotectin, we are unable to assume causality. 
Whilst we can hypothesize that aberrant motility is related to remote 
inflammation and may help explain functional abdominal symptoms, it maybe 
patients feelings of pain and wellbeing affects motility secondarily.  
 
In conclusion, we have shown the motility variance in unaffected bowel quantified 
using MRI has moderate negative correlation with both patient symptoms and 
fecal calprotectin in CD patients. 
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Figure legends  
 
Figure 1 Motility maps (red = high motility, blue = low motility) for 4 subjects 
with radiologist drawn ROIs (red) around morphologically normal small bowel. A: 
Low mean motility (0.04) low variance score (0.003). B: High mean motility (0.47), 
low variance score (0.005), C: Low mean motility (0.11) moderate variance score 
(0.025) & D: moderate mean motility (0.29), high variance (0.03). 
 
Figure 2. The contractions per minute (CPM) score was measured by plotting the 
change in luminal diameter over time and counting the number of instances where 
a decrease in bowel diameter was greater than 10% less than the mean bowel 
diameter for that time series. The two ROIs are depicted in 2A with the respective 
time curves for the two ROIs in 2B and 2C. Horizontal black line represents mean 
diameter, dotted red line the mean diameter minus 10% and the red stars signify 
significant contractions.  
 Figure 3. Scatter plot demonstrating a significant negative relationship between 
HBI score and global motility variance (Rho = -0.45, P <0.001). 
Table legends  
Parameter Number of Patients 
Disease Duration 
<1year 5 
1-5 year 20 
5-10 year 14 
>10 year 14 
  
Disease location 
Terminal ileal 11 
Colon 17 
Ileocolonic  25 
  
Medications*  
None 7 
5-ASA 21 
Immunomodulators 28 
Biological agents 16 
  
Surgical history 
None 34 
1 operation 11 
2 operations 8 
 
Table 1 Summary of patient demographics.  
* None = no CD specific medication, 5-ASA = 5-ASA medication alone, 
Immunomodulators = Immunomodulators including Methotrexate, Azathioprine 
& 6-Mercaptopurine) & Biological agents = biologics used alone or in conjunction 
with other agents.  
 
Table 2. Median and range of motility and CD activity score values 
 
Table 3. Correlation between CD activity endpoints and motility metrics. 
Metric Median Min Max 
    
1-Mean CPM 2 0.5 3.5 
    
2- Global Motility Mean 0.33 0.18 0.51 
    
3. Global Motility Variance 0.01 0.0014 0.0338 
 
CALP 336 0 1280 
    
HBI 3 0 16 
Wellbeing 1 0 4 
Abdominal pain 1 0 3 
Liquid stool 1 0 13 
 
1. CPM 
2. Global Motility 
Mean 
3. Global Motility 
Variance 
    
fC R = -0.22, P = 0.1 R = -0.09, P = 0.51 R = -0.33, P = 0.015* 
    
HBI R = 0.1, P = 0.46 R = 0.06, P = 0.68 R = -0.45, P <0.001* 
 HBI Parameter Correlation R 
Wellbeing -0.4, p = 0.003* 
Abdominal pain -0.27, p = 0.05* 
Liquid stool -0.4, p = 0.0025* 
Abdominal mass 0.15, p = 0.3 
  
 
Table 4. HBI indices correlated against global motility variance (R = correlation 
coefficient and p = corresponding significance value. * represents statistical 
significance <0.05).  
Variable Odds ratio (95% CI) p value 
Wellbeing (5 point scale, higher scores are worse) 
Age 0.99 (0.95-1.03) 0.64 
Sex 0.29 (0.07-1.03) 0.06 
Current smoker 0.53 (0.05-4.21) 0.57 
Previous surgery 0.20 (0.03-1.02) 0.07 
Medication  0.86 (0.41-1.83) 0.69 
BMI 1.07 (0.90-1.26) 0.46 
Disease Duration 1.04 (0.91-1.19) 0.56 
Faecal Calprotectin level 1.00 (0.98-1.01) 0.25 
Global motility variance 0.19 (0.06-0.50) <0.001 
Abdominal Pain (4 point scale, higher scores are worse) 
Age 0.98 (0.94-1.03) 0.47 
Sex 0.25 (0.06-1.00) 0.06 
Current smoker 0.06 (0.002-0.60) 0.04 
Previous surgery 0.23 (0.04-1.25) 0.11 
Medication  0.83 (0.38-1.88) 0.65 
BMI 1.20 (1.03-1.42) 0.03 
Disease Duration 1.00 (0.87-1.15) 0.98 
Faecal Calprotectin level 1.00 (0.97-1.03) 0.70 
Global motility variance 0.26 (0.08-0.67) 0.004 
Number of diarrhoeal stools Incidence rate ratio 
(95% CI) 
p value 
Age 1.00 (0.98-1.03) 0.71 
Sex 0.24 (0.23-0.44) <0.001 
Current smoker 0.66 (0.002-0.60) 0.43 
Previous surgery 1.89 (0.04-1.25) 0.12 
Medication  1.08 (0.38-1.88) 0.67 
BMI 1.04 (1.03-1.42) 0.35 
Disease Duration 0.92 (0.87-1.15) 0.01 
Faecal Calprotectin level 1.00 (1.00-1.01) 0.07 
Global motility variance 0.39 (0.23-0.61) <0.0001 
 
Table 5 Relationship between HBI components of wellbeing, abdominal pain and 
number of diarrheal stools/day and demographic, clinical and motility variables, 
derived by ordinal logistic or negative binomial regression and expressed as odds 
ratios or incidence rate ratios respectively. Baseline categories for categorical 
variables as follows: sex = female, smoker = non-smoker, previous surgery = no 
prior surgery, medication   (0 = no medication, 1= 5-ASA, 2 = Immunomodulators, 
3 = immunologics. Significant results are shown in italics.  
 1.5 T Siemens Avanto 3T Philips Achieva 
  Motility Anatomical Motility Anatomical 
Sequence name  TrueFISP HASTE BTFE HASTE 
Plane Coronal coronal/axial coronal coronal/axial 
Field of view (mm) Variable Variable Variable Variable 
No. Slices 20 20/26 20 40/45 
 Appendix 1. Motility sequences at the two field strengths along with the 
anatomical sequences used to identify diseased segments of bowel. 
 
Stacks 6-16 1/4 6-15 1/2 
Repetition time (ms) 3.85 1,200/800 1.96 517/1450 
Echo time (ms) 1.91 86/86 0.98 65/70 
Image matrix 256 x 184 256x195 200 x 167 526x199/288x231 
Slice thickness (mm) 10 4/4 10 7/4 
Slice gap (mm) 10 5.2/5.4 10 8/5 
Averages 1 1 1 1 
Flip angle 61 50 45 90 
 
     
